Date: 20 October 2017
Dechra® Pharmaceuticals PLC
Results of Annual General Meeting (AGM)
AGM Meeting Date: 1pm on 20 October 2017
Issued Share Capital at meeting date: 93,415,750
Number of shareholders in attendance: 12
All resolutions were passed on a show of hands.
Details of the proxy voting instructions lodged prior to the AGM are set out below:
Resolution (No. as noted on proxy form)
|
Total For (1) |
Total Against |
Withheld (2) |
||
|
No. of votes |
% of vote |
No. of votes |
% of vote |
No. of votes |
Resolution 1: To receive the accounts, the Strategic Report, the Directors' Report and the Auditor's Report
|
69,787,352 |
94.83 |
3,801,367 |
5.17 |
176,986 |
Resolution 2: To receive and approve the Directors' Remuneration Report
|
66,111,495 |
94.18 |
4,086,647 |
5.82 |
3,567,713 |
Resolution 3: To receive and approve the Directors' Remuneration Policy
|
72,932,631 |
98.88 |
823,955 |
1.12 |
8,619 |
Resolution 4: To declare a final dividend
|
73,764,546 |
100 |
0 |
0.00 |
659 |
Resolution 5: To elect Richard Cotton
|
72,195,608 |
97.87 |
1,568,938 |
2.13 |
659 |
Resolution 6: To elect Lawson Macartney
|
73,401,877 |
99.51 |
361,469 |
0.49 |
1,859 |
Resolution 7: To re-elect Tony Rice
|
66,992,715 |
92.48 |
5,448,270 |
7.52 |
1,324,220 |
Resolution 8: To re-elect Ian Page
|
72,285,663 |
98.00 |
1,478,883 |
2.00 |
659 |
Resolution 9: To re-elect Anthony Griffin
|
72,279,341 |
97.99 |
1,485,205 |
2.01 |
659 |
Resolution 10: To re-elect Julian Heslop
|
73,500,858 |
99.64 |
263,688 |
0.36 |
659 |
Resolution 11: To re-elect Ishbel Macpherson
|
73,144,501 |
99.16 |
620,045 |
0.84 |
659 |
Resolution 12: To reappoint PricewaterhouseCoopers as external auditor of the Company
|
73,756,778 |
99.99 |
7,318 |
0.01 |
1,109 |
Resolution 13: To authorise the Audit Committee to determine the remuneration of the external auditor
|
73,763,069 |
100 |
1,027 |
0.00 |
1,109 |
Resolution 14: To authorise the Directors to allot shares to specific limits
|
69,568,791 |
94.32 |
4,191,805 |
5.68 |
4,609 |
Resolution 15: To disapply the pre-emption rights
|
72,858,327 |
98.78 |
903,219 |
1.22 |
3,659 |
Resolution 16: To disapply additional pre-emption rights
|
67,395,228 |
91.37 |
6,366,318 |
8.63 |
3,659 |
Resolution 17: To authorise the Company to purchase its own shares
|
72,978,224 |
99.07 |
685,466 |
0.93 |
101,515 |
Resolution 18: To call general meetings (other than an AGM) on not less than 14 clear days' notice
|
71,828,591 |
97.38 |
1,935,505 |
2.62 |
1,109 |
Resolution 19: (a) To approve the rules of the LTIP 2017; and (b) To authorise the Directors to adopt further schemes based on the LTIP 2017
|
70,433,043 |
95.49 |
3,328,963 |
4.51 |
3,199 |
Notes
1. Includes discretionary votes.
2. A "vote withheld" is not a vote in law and is not counted in the calculation of the proportion of votes "For" and "Against" a resolution.
3. Resolutions 1 to 14 and Resolution 19 were ordinary resolutions, requiring more than 50% of shareholder votes to be "for" the resolutions.
4. Resolutions 15 to 18 were special resolutions, requiring more than 75% of shareholder votes to be "for" the resolutions.
5. Votes tendered in respect of 73,765,205 shares representing 78.96% of the issued share capital.
In accordance with Listing Rule 9.6.2R, a copy of the resolutions passed as special business at the AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm.
For further information
Melanie Hall, Company Secretary
Telephone number: 01606 814730
About Dechra
Dechra is an international specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. The majority of Dechra's products are focused on key therapeutic categories where we have leading market positions, and many of our products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information, please visit: www.dechra.com.
Trademarks
Trademarks appear throughout this document in italics. Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.